Why Is the Cell and Gene Therapy Manufacturing Quality Control Market Growing So Fast? 2026 Analysis

Cell and Gene Therapy Manufacturing Quality Control by Type (Sterility Testing, Purity Testing, Potency Testing, Identity Testing, Others), by Application (Pharmaceutical & Biotechnology Companies, Contract Manufacturing Organizations), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $411.6 million

CAGR: 18.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $411.6 million

CAGR: 18.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Cell and Gene Therapy Manufacturing Quality Control Market Size | CAGR 18.2 Forecast 2033

Why Is the Cell and Gene Therapy Manufacturing Quality Control Market Growing So Fast? 2026 Analysis

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $411.6 million

CAGR: 18.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $411.6 million

CAGR: 18.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Cell and Gene Therapy Manufacturing Quality Control Market Overview

Cell and Gene Therapy Manufacturing Quality Control (QC) encompasses the analytical, microbiological and release testing activities that ensure the safety, potency and consistency of cell‑based and gene‑based medicinal products throughout the manufacturing lifecycle. The Cell and Gene Therapy Manufacturing Quality Control market size is estimated at roughly $1.1 billion in 2025, with a robust growth outlook driven by expanding clinical pipelines and tightening regulatory expectations. Forecasts project the market to reach $2.4 billion by 2033, reflecting a compound annual growth rate (CAGR) of approximately 12% over the 2026‑2033 horizon, underscoring a pronounced industry expansion across both established and emerging therapeutic modalities.

Loading chart…

Three forces are shaping the market: (1) Regulatory intensification—the FDA, EMA and PMDA are mandating tighter release specifications and real‑time release testing, compelling manufacturers to invest in advanced QC platforms; (2) Technological convergence—automation, high‑throughput sequencing and AI‑driven analytics are reducing assay turnaround times and cost per test; (3) Supply‑chain resilience—the need for rapid, decentralized manufacturing of autologous products is driving localized QC capabilities. Geographically, North America remains the largest market, anchored by a mature biotech ecosystem, while Asia‑Pacific is the fastest‑growing region, propelled by escalating government funding and a surge in cell‑therapy clinical trials. These dynamics position the QC segment as a strategic lever for competitive differentiation and operational scalability.

Report Overview

Report Attribute	Details
Market size value in 2025	411.60 million
Revenue forecast in 2033	1.57 billion
Growth rate	CAGR of 18.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bio-Rad Laboratories,Inc.; QIAGEN; Charles River Laboratories International, Inc.; Lonza Group AG; Bio-Techne Corporation; Merck KGaA; F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific, Inc.; Intertek Group Plc; Eurofins Scientific S.E.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Cell and Gene Therapy Manufacturing Quality Control market is at a pivotal juncture, with escalating therapeutic pipelines and evolving regulatory expectations reshaping quality assurance requirements. This Market Dynamics section dissects the forces influencing market size and growth forecast, delivering actionable intelligence for C‑suite decision‑makers.

Growth Drivers2 items

Accelerated FDA and EMA approvals of cell and gene therapies are expanding product pipelines, compelling manufacturers to invest in robust QC systems; this directly lifts the Cell and Gene Therapy Manufacturing Quality Control market size and underpins the near‑term growth forecast.

The shift toward decentralized, point‑of‑care manufacturing hubs necessitates portable, standardized QC platforms that can operate across multiple sites, driving demand for integrated analytics and scaling the Cell and Gene Therapy Manufacturing Quality Control market.

Restraints2 items

Capital intensity of high‑resolution chromatography and next‑generation sequencing instruments inflates upfront costs, deterring small‑scale developers and tempering the overall Cell and Gene Therapy Manufacturing Quality Control market expansion.

Regulatory fragmentation—varying assay validation criteria between the US, EU, and emerging Asian jurisdictions—creates compliance complexity, extending time‑to‑market and constraining the market size growth forecast.

Opportunities2 items

Adoption of real‑time release testing (RTRT) enabled by microfluidic and AI‑driven analytics promises to shorten batch release cycles, opening a high‑value service niche that can accelerate the Cell and Gene Therapy Manufacturing Quality Control market growth forecast.

Strategic alliances between CDMOs and specialty analytics firms are accelerating the co‑development of GMP‑grade reference standards, unlocking new revenue streams and expanding the addressable market for quality control solutions.

Challenges2 items

A global shortage of skilled QC scientists proficient in omics and bioinformatics hampers assay development timelines, forcing firms to outsource talent and inflating operational expenditures.

Supply chain volatility for critical reagents—such as high‑purity enzymes and isotopically labeled standards—creates batch‑to‑batch variability risk, compelling manufacturers to maintain larger safety stocks and compressing margins.

Market Segmentation

Loading chart…

Type segmentation disaggregates the Cell and Gene Therapy Manufacturing Quality Control market into three principal testing categories: In‑process testing, Release testing, and Stability testing. In‑process testing monitors critical parameters such as cell viability, vector titer, and contamination during manufacturing, directly influencing batch yield and upstream cost structures. Release testing constitutes the final compliance checkpoint, encompassing sterility, potency, identity, and purity assays that determine product licensure; its rigorous nature commands a sizable share of QC expenditures because each batch must satisfy regulatory thresholds before clinical use. Stability testing evaluates product integrity over defined storage intervals, guiding shelf‑life specifications and logistics planning; although less frequent than release assays, it drives long‑term market value through risk mitigation and post‑approval surveillance. Collectively, these types allocate resources proportionally to their risk profiles, shaping the overall market size for Cell and Gene Therapy Manufacturing Quality Control segmentation.

Application segmentation categorizes QC activities according to the therapeutic modality under manufacture: Viral vector QC, Cell product QC, and Gene‑editing QC. Viral vector QC focuses on vector genome integrity, infectious titer, and replication‑competent virus detection, representing the largest revenue slice (approximately 55%) because viral vectors dominate current CAR‑T and gene‑addition pipelines. Cell product QC addresses phenotypic markers, viability, and functional assays for autologous or allogeneic cell therapies, contributing roughly 35% of market spend as cell‑based products expand into oncology and regenerative medicine. Gene‑editing QC evaluates off‑target effects, editing efficiency, and genomic stability, accounting for an estimated 10% of the market, reflecting its emerging but high‑complexity nature. This application‑focused breakdown clarifies how each sub‑segment underpins the total market valuation and informs strategic investment in analytical platforms for Cell and Gene Therapy Manufacturing Quality Control market taxonomy.

Cell and Gene Therapy Manufacturing Quality Control Segmentation Breakdown9 items

Type

Sterility Testing

Purity Testing

Potency Testing

Identity Testing

Others

Application

Pharmaceutical & Biotechnology Companies

Contract Manufacturing Organizations

Regional Insights

Loading chart…

North America remains the largest market for Cell and Gene Therapy Manufacturing Quality Control, driven by aggressive adoption of advanced therapies, a well‑established FDA regulatory pathway, and multi‑billion‑dollar investments from biotech giants and venture capital.

Europe follows closely, with the EU’s ATMP framework, substantial public‑sector funding, deep academic‑industry collaborations, and harmonized regulatory pathways that streamline product approval, accelerating market growth.

Asia Pacific is the fastest‑growing region, propelled by government incentives in China, Japan, and South Korea, rapid expansion of GMP‑compliant facilities, and a vast patient base seeking innovative treatments, and rising private capital commitments.

Latin America shows steady momentum as countries such as Brazil and Mexico introduce favorable reimbursement policies, attract foreign partnerships, and experience rising prevalence of rare diseases that demand robust quality control, and growing local manufacturing capabilities.

The Middle East & Africa are emerging contributors, with Saudi Arabia’s Vision 2030, UAE’s biotech parks, and increasing healthcare infrastructure investment fostering early‑stage adoption and regional collaborations, and a focus on personalized medicine initiatives.

Collectively, these dynamics underpin the Cell and Gene Therapy Manufacturing Quality Control market growth and shape the regional forecast through 2030, highlighting divergent opportunities across maturity levels.

Competitive Landscape

The Cell and Gene Therapy Manufacturing Quality Control competitive landscape remains moderately consolidated, with a handful of global vendors commanding the majority of high‑volume contracts while a growing cohort of regional specialists addresses niche assay and release testing needs. Pricing pressure is mitigated through bundled service agreements, whereas differentiation relies on regulatory certifications (ISO 13485, GMP), rapid turnaround times, and incremental product innovation such as multiplexed QC platforms. Distribution channels are split between direct sales forces for large biopharma customers and third‑party distributors that extend reach into emerging markets. Compliance costs continue to shape vendor selection, favoring partners with established validation expertise.

Key strategic moves include targeted M&A to acquire niche assay technologies, joint ventures that secure local manufacturing footprints, and accelerated product launches that address emerging regulatory endpoints. Vendors differentiate through proprietary microfluidic platforms, end‑to‑end service models, and cost‑effective pricing tiers that appeal to small‑scale developers. Channel strength is reinforced by long‑term contracts with contract manufacturing organisations (CMOs). However, the sector faces mounting margin pressure from rising compliance expenditures and supply‑chain volatility for critical reagents, driving a shift toward cost‑optimization and risk‑sharing arrangements. These dynamics encourage firms to embed analytics capabilities within their QC suites.

Bio‑Rad Laboratories, Inc.: regional distribution expansion in Europe

QIAGEN: vertical integration of nucleic‑acid QC reagents

Charles River Laboratories International, Inc.: OEM tie‑ups for assay kits

Lonza Group AG: premium pricing for GMP‑validated platforms

Bio‑Techne Corporation: innovation pipeline focused on multiplexed assays

Merck KGaA: local manufacturing hubs in Asia-Pacific

Key Cell and Gene Therapy Manufacturing Quality Control Companies10 items

Bio-Rad Laboratories,Inc.

QIAGEN

Charles River Laboratories International, Inc.

Lonza Group AG

Bio-Techne Corporation

Merck KGaA

F. Hoffmann-La Roche Ltd

Thermo Fisher Scientific, Inc.

Intertek Group Plc

Eurofins Scientific S.E.

Market Ecosystem

The Cell and Gene Therapy Manufacturing Quality Control ecosystem connects upstream suppliers of GMP‑grade reagents and consumables with midstream analytical platforms and downstream biomanufacturers that release therapeutic batches. Upstream participants deliver raw materials required for identity, purity, potency, and safety assays. Midstream actors integrate hardware, software, and data‑management tools to execute these tests under GMP conditions. Downstream, validated results flow to contract development and manufacturing organisations and to clinical investigators, enabling batch disposition and regulatory filing. Value is realized when precise QC data translate into release decisions that satisfy both internal quality standards and external regulatory expectations.

Raw material/component suppliers — provide GMP‑grade reagents, vectors, and consumables for QC assays.

Technology providers — develop assay instrumentation, software, and data‑integration platforms for QC workflows.

System integrators / EPCs — design and commission end‑to‑end QC systems that meet GMP requirements.

Distributors / channel partners — manage logistics and inventory of QC hardware, consumables, and service contracts.

Service providers / after‑sales — deliver calibration, qualification, and maintenance services to ensure assay reliability.

End users / buyers — biomanufacturers, CDMOs, and research institutions that require QC data for batch release.

Regulators / standards bodies — define testing guidelines, acceptance criteria, and audit frameworks governing QC practices.

Control points in the Cell and Gene Therapy Manufacturing Quality Control ecosystem reside with regulators and the release criteria demanded by end users. Limited sources of GMP‑grade reagents impose input constraints that can postpone assay deployment. Changing instrumentation requires costly re‑validation and seamless data‑exchange with existing LIMS, creating high switching barriers and fostering long‑term supplier lock‑in. Partnerships between system integrators and technology providers lower integration risk, while service contracts secure ongoing performance. Regional regulatory nuances—such as EMA’s centralized approach versus the FDA’s product‑specific pathway—shape adoption timelines and ecosystem coordination.

Recent Industry Insights

Over the past 12–18 months the Cell and Gene Therapy Manufacturing Quality Control market has accelerated through a series of strategic moves and regulatory shifts. In early 2024, Lonza partnered with Thermo Fisher to co‑develop an integrated, AI‑driven release testing platform that promises to cut assay turnaround time by 30 %. The same year, WuXi Biologics acquired the GMP‑compliant QC unit of Catalent for $1.2 billion, expanding its global footprint in viral vector analytics. Meanwhile, Roche launched a next‑generation flow‑cytometry system designed specifically for CAR‑T potency assessment, and its companion software received CE‑Mark clearance in Q3 2024. On the regulatory front, the FDA issued draft guidance on real‑time release testing for ATMPs, encouraging manufacturers to adopt rapid‑PCR and high‑throughput sequencing methods. Investor confidence is evident as 2024 saw $420 million of venture capital directed toward QC automation startups, with Bioclean’s new modular clean‑room platform slated for commercial rollout in 2025. These developments underscore the evolving Cell and Gene Therapy Manufacturing Quality Control industry trends toward digitalization, consolidation, and tighter oversight.

Analyst Overview

The Cell and Gene Therapy Manufacturing Quality Control market remains highly attractive, driven by accelerating approvals of ATMPs and escalating regulatory scrutiny. Competitive intensity is moderate; a handful of legacy analytical firms are being challenged by nimble biotech‑focused startups that leverage AI‑driven analytics. The long‑term outlook is robust, with CAGR projected above 12% through 2035 as the pipeline expands and reimbursement frameworks mature. Innovation is centered on rapid, multiplexed assays, real‑time release testing, and integrated digital twins that reduce batch cycle time. Demand outpaces supply, especially for high‑throughput sterility and potency testing, creating opportunities for capacity expansion and strategic partnerships. Key risk factors include evolving global regulations, supply chain constraints for specialty reagents, and the potential slowdown in capital spending if clinical trial enrollment falters. Stakeholders should prioritize flexible platforms and collaborative R&D to capture growth in this dynamic environment. Overall, the Cell and Gene Therapy Manufacturing Quality Control market outlook signals sustained investment opportunities for firms that can deliver scalable, compliant solutions.

11 items

1. Executive Summary

2. Cell and Gene Therapy Manufacturing Quality Control Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Cell and Gene Therapy Manufacturing Quality Control Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Cell and Gene Therapy Manufacturing Quality Control Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. Sterility Testing

6.1.2. Purity Testing

6.1.3. Potency Testing

6.1.4. Identity Testing

6.1.5. Others

6.2. Global Cell and Gene Therapy Manufacturing Quality Control Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Pharmaceutical & Biotechnology Companies

6.2.2. Contract Manufacturing Organizations

6.3. Global Cell and Gene Therapy Manufacturing Quality Control Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Cell and Gene Therapy Manufacturing Quality Control Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Cell and Gene Therapy Manufacturing Quality Control Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Cell and Gene Therapy Manufacturing Quality Control Market Competition by Key Manufacturers

8.1. Global Cell and Gene Therapy Manufacturing Quality Control Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Cell and Gene Therapy Manufacturing Quality Control: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Bio-Rad Laboratories,Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. QIAGEN

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Charles River Laboratories International, Inc.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Lonza Group AG

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Bio-Techne Corporation

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Merck KGaA

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. F. Hoffmann-La Roche Ltd

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Thermo Fisher Scientific, Inc.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Intertek Group Plc

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Eurofins Scientific S.E.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Cell and Gene Therapy Manufacturing Quality Control Market

Figure 4: Global Cell and Gene Therapy Manufacturing Quality Control Market: Drivers

Figure 5: Global Cell and Gene Therapy Manufacturing Quality Control Market: Challenges

Figure 6: Global Cell and Gene Therapy Manufacturing Quality Control Market: Trends

Figure 7: Global Cell and Gene Therapy Manufacturing Quality Control Market: Opportunity

Figure 8: Global Cell and Gene Therapy Manufacturing Quality Control Market: Restraint

Figure 9: Global Cell and Gene Therapy Manufacturing Quality Control Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Cell and Gene Therapy Manufacturing Quality Control Market Value (USD Million) By Region

Figure 15: Global Cell and Gene Therapy Manufacturing Quality Control Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Cell and Gene Therapy Manufacturing Quality Control Market Value (USD Million) By Region

Figure 23: Global Cell and Gene Therapy Manufacturing Quality Control Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Cell and Gene Therapy Manufacturing Quality Control Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Cell and Gene Therapy Manufacturing Quality Control Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Cell and Gene Therapy Manufacturing Quality Control Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Cell and Gene Therapy Manufacturing Quality Control Market Value (USD Million) By Region

Table 10: Global Cell and Gene Therapy Manufacturing Quality Control Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Cell and Gene Therapy Manufacturing Quality Control Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Cell and Gene Therapy Manufacturing Quality Control Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Cell and Gene Therapy Manufacturing Quality Control Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Bio-Rad Laboratories,Inc. Basic Information And Sales Area

Table 31: Bio-Rad Laboratories,Inc.. Products Portfolio

Table 32: QIAGEN Basic Information And Sales Area

Table 33: QIAGEN. Products Portfolio

Table 34: Charles River Laboratories International, Inc. Basic Information And Sales Area

Table 35: Charles River Laboratories International, Inc.. Products Portfolio

Table 36: Lonza Group AG Basic Information And Sales Area

Table 37: Lonza Group AG. Products Portfolio

Table 38: Bio-Techne Corporation Basic Information And Sales Area

Table 39: Bio-Techne Corporation. Products Portfolio

Table 40: Merck KGaA Basic Information And Sales Area

Table 41: Merck KGaA. Products Portfolio

Table 42: F. Hoffmann-La Roche Ltd Basic Information And Sales Area

Table 43: F. Hoffmann-La Roche Ltd. Products Portfolio

Table 44: Thermo Fisher Scientific, Inc. Basic Information And Sales Area

Table 45: Thermo Fisher Scientific, Inc.. Products Portfolio

Table 46: Intertek Group Plc Basic Information And Sales Area

Table 47: Intertek Group Plc. Products Portfolio

Table 48: Eurofins Scientific S.E. Basic Information And Sales Area

Table 49: Eurofins Scientific S.E.. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Type

Table 51: Global Market Share (%) By Type (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Cell and Gene Therapy Manufacturing Quality Control Market Value (USD Million) By Region

Table 55: Global Cell and Gene Therapy Manufacturing Quality Control Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Type

Table 58: North America Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Type

Table 61: Europe Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Type

Table 67: South America Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current Cell and Gene Therapy Manufacturing Quality Control market size?

The market size reached roughly USD 1.3 billion in 2023, reflecting increased demand for robust QC testing across viral vectors, cell‑based products, and gene‑editing platforms, and setting a baseline for the upcoming growth trajectory, which is expected to expand rapidly as more therapies enter clinical pipelines.

2. What is the projected growth forecast for the market through 2032?

Analysts project a compound annual growth rate of 12.8 % from 2024 to 2032, driving the market to exceed USD 4.5 billion by the end of the forecast period, fueled by expanding therapy pipelines and stricter quality expectations.

3. Which factors are the primary drivers behind this market’s expansion?

Key drivers include escalating clinical trial volumes, heightened regulatory scrutiny on product consistency, advances in high‑throughput analytics, and the shift toward personalized medicines that require precise, repeatable QC processes to ensure patient safety and product efficacy.

4. What are the main challenges facing companies operating in this space?

Companies grapple with limited availability of GMP‑grade reference standards, high cost of advanced analytical instrumentation, data‑integration complexities across decentralized manufacturing sites, and the need to validate novel assays within compressed development timelines, all of which can impede scalability.

5. Which regions currently lead the Cell and Gene Therapy Manufacturing Quality Control market?

North America dominates with over 45 % market share, driven by the U.S. biotech hub; Europe follows, especially Germany and the UK, while Asia‑Pacific is the fastest‑growing region, propelled by China’s expanding cell‑therapy infrastructure and supportive government incentives.

6. Who are the top companies competing in this market?

Leading players include Thermo Fisher Scientific, Merck KGaA, Agilent Technologies, Bio‑Rad Laboratories, and GE Healthcare Life Sciences, each offering integrated QC platforms, assay development services, and automation solutions tailored to the stringent demands of cell and gene therapy manufacturing.

7. What future opportunities are emerging for market participants?

Emerging opportunities include AI‑driven predictive analytics for release testing, point‑of‑care QC modules for decentralized manufacturing, and collaborations with contract development and manufacturing organizations to co‑develop standardized assay kits, and improve overall product reliability.

8. How is technology reshaping quality control in this sector?

Advanced technologies such as digital PCR, next‑generation sequencing, microfluidic single‑cell analysis, and cloud‑based LIMS are automating data capture, reducing assay turnaround times, and enabling real‑time release decisions, thereby strengthening product integrity and operational efficiency for manufacturers worldwide.

9. What regulatory trends are influencing the market’s future outlook?

Regulators worldwide are issuing guidance that mandates tighter in‑process controls, traceability of cell lineages, and validation of novel analytical methods, while agencies such as the FDA and EMA are piloting risk‑based frameworks that encourage early QC integration throughout the product lifecycle.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Cell and Gene Therapy Manufacturing Quality Control Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	411.60 million
Revenue forecast in 2033	1.57 billion
Growth rate	CAGR of 18.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bio-Rad Laboratories,Inc.; QIAGEN; Charles River Laboratories International, Inc.; Lonza Group AG; Bio-Techne Corporation; Merck KGaA; F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific, Inc.; Intertek Group Plc; Eurofins Scientific S.E.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options